Swedish Orphan Biovitrum presents first positive Kiobrina® clinical phase II data
(Thomson Reuters ONE) -
Stockholm, Sweden - May 6, 2010 - Swedish Orphan Biovitrum (STO: BVT) today
presents as a poster clinical phase II results from the first study showing that
Kiobrina® added to infant formula significantly improve growth of preterm
infants as compared to placebo after 1 week of treatment. The poster is
presented at "The Power of Programming 2010. International conference on
developmental origins of health and disease" in Munich, Germany.
Please find the poster enclosed.
"This is an interesting project and Kiobrina holds a great opportunity to fill a
medical need in neonatal care. Based on these results and those from a second
clinical phase II trial of Kiobrina in pasteurized mother's milk we are now
planning for a phase III study in preterm infants", said Peter Edman, CSO of
Swedish Orphan Biovitrum
About Kiobrina
Kiobrina is a recombinant human bile-salt-stimulated lipase (rhBSSL) developed
by Swedish Orphan Biovitrum, aiming to improve growth and development in preterm
infants. The rationale for adding rhBSSL to pasteurized breast milk or infant
formula is to restore the natural lipase activity level that is either lost on
pasteurization or totally absent in formula.
About Swedish Orphan Biovitrum
On January 14, 2010, Biovitrum AB (publ) completed the acquisition of Swedish
Orphan International Holding AB and created Swedish Orphan Biovitrum - a leading
company focused on treatment of rare diseases.
Swedish Orphan Biovitrum is a Swedish based specialty pharmaceutical company
with an international market presence. The company is focused on providing and
developing orphan and niche specialist pharmaceuticals to patients with high
medical needs. The portfolio consists of about 60 marketed products and an
emerging late stage clinical development pipeline within rare diseases. Swedish
Orphan Biovitrum has pro-forma revenues 2009e of about 2 BSEK and approximately
500 employees. The head office is located in Sweden and the share (STO: BVT) is
listed on NASDAQ OMX Stockholm. For more information please visit
www.biovitrum.com
For more information please contact:
Swedish Orphan Biovitrum:
Peter Edman, CSO
Phone. +46 8 697 21 77
Erik Kinnman, EVP Investor Relations
Phone: +46 73 422 15 40
erik.kinnman(at)biovitrum.com
Martin Nicklasson, CEO
Phone: +46 8 697 20 00
The clinical phase II studies have been carried out partially with research
funding from the European Community's Sixth Framework Program (The Early
Nutrition Programming Project, www.metabolic-programming.org
author´s views and does not necessarily reflect the views of the European
Community or European Commission or their future policy, and they are not
liable for any use that may be made of the information contained herein. The
information in this document is provided as is and no guarantee or warranty is
given that the information is fit for any particular purpose. The user thereof
uses the information at its sole risk and liability.
Swedish Orphan Biovitrum may be required to disclose the information provided
herein pursuant to the Swedish Securities Markets Act. The information was
provided for public release on May 6, 2010 at 8:30 a.m. CET.
[HUG#1412421]
Press release in PDF format: http://hugin.info/134557/R/1412421/364686.pdf
Poster Kiobrina clinical phase II results: http://hugin.info/134557/R/1412421/364689.pdf
Unternehmensinformation / Kurzprofil:
Datum: 06.05.2010 - 08:34 Uhr
Sprache: Deutsch
News-ID 20383
Anzahl Zeichen: 0
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 194 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Swedish Orphan Biovitrum presents first positive Kiobrina® clinical phase II data"
steht unter der journalistisch-redaktionellen Verantwortung von
Biovitrum (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
